^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLL2 mutation

    i
    Other names: MLL2, myeloid/lymphoid or mixed-lineage leukemia 2
    Entrez ID:
    100512962
    Related biomarkers:
    Others
    7ms
    Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers. (PubMed, Explor Target Antitumor Ther)
    This analysis provides clinical and molecular details about the phenotypes of ARID1A cancers, in particular the subgroup of gynecologic cancers. The high frequency of concurrent mutations in the phosphoinositide 3-kinase (PI3K) pathway among endometrioid endometrial cancers may support the proposal of a new treatment strategy based on the combination of ataxia telangiectasia and Rad3-related (ATR) inhibitor and PIK3CA inhibitor.
    Journal • Tumor mutational burden
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • KMT2D (Lysine Methyltransferase 2D) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2)
    |
    PIK3CA mutation • PTEN mutation • ARID1A mutation • MLL2 mutation
    |
    FoundationOne® CDx
    8ms
    Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group (IWCLL 2023)
    Ex vivo drug treatments included: BCL2i (inhibitor): venetoclax; MCL-1i: AZD5991, S63845 and BCLXLi: A133. The genomic landscape of BCL2-R CLL is characterized by a high frequency of trisomy 12, subclonal NOTCH and RAS pathway mutations, as well as BCL2 and MLL2 mutations. Protein expression, BH3 profiling and viability assays data are consistent with nearly exclusive dependence on Bcl-2.
    IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SF3B1 (Splicing Factor 3b Subunit 1) • KMT2D (Lysine Methyltransferase 2D) • BCL2L1 (BCL2-like 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CREBBP (CREB binding protein) • BIRC3 (Baculoviral IAP repeat containing 3) • BCL2L11 (BCL2 Like 11) • EP300 (E1A binding protein p300) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • ANXA5 (Annexin A5)
    |
    TP53 mutation • BRAF mutation • NOTCH1 mutation • RAS mutation • KMT2D mutation • EZH2 mutation • MYD88 L265P • BCL2 expression • BCL2 mutation • MCL1 expression • BCL2 G101V • MLL2 mutation • BCL2 rearrangement • TS 12
    |
    Venclexta (venetoclax) • S63845 • AZD5991
    9ms
    Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients (IASLC-WCLC 2023)
    Though subset analysis of randomized clinical trials did not show a predictive benefit of high TMB in patients who received chemoimmunotherapy in SCLC, we found that high TMB may be a prognostic factor in SCLC patients receiving chemotherapy +/- PD-L1 ICI. Although our study did not find GA associated with exceptionally favorable TTNT, further studies focused on specific alterations are needed to investigate additional genomic markers of chemoimmunotherapy effectiveness in SCLC, including RNA expression analysis.
    Clinical • Real-world evidence • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    TP53 mutation • TMB-H • PTEN mutation • KMT2D mutation • MLL2 mutation • MLL mutation • MYCL amplification
    almost2years
    Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy (IASLC-WCLC 2022)
    Preliminary data seem to support the idea of ​​the existence of different profiles depending on the metastatic site. However, the small sample size means that further studies are required to validate these data.
    Clinical • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • NF1 (Neurofibromin 1) • KMT2D (Lysine Methyltransferase 2D) • FLT1 (Fms-related tyrosine kinase 1) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • SOX2 • EPHA3 (EPH receptor A3) • KLHL6 (Kelch Like Family Member 6)
    |
    TP53 mutation • KRAS mutation • BRCA1 mutation • EGFR mutation • ATM mutation • NF1 mutation • KMT2D mutation • APC mutation • MLL2 mutation
    |
    Guardant360® CDx
    almost2years
    A PHASE 2 STUDY OF NEOADJUVANT PERTUZUMAB, ATEZOLIZUMAB, DOCETAXEL AND TRASTUZUMAB IN HER2-POSITIVE EARLY BREAST CANCER (NEO-PATH, KCSG BR 18-23) (GBCC 2022)
    Neoadjuvant PATH regimen showed favorable efficacy and safety profiles in stage II-III HER2-positive EBC, Luminal subtype and MYC amplification were associated with worse response. NEO-PATH provides evidence of combining immunotherapy and anti-HER2 treatment as a potential new therapeutic option.
    Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KMT2D (Lysine Methyltransferase 2D) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2)
    |
    PD-L1 expression • HER-2 positive • TP53 mutation • HER-2 amplification • PIK3CA mutation • MYC amplification • HR negative • KMT2D mutation • MLL2 mutation • MLL mutation • TP53 amplification
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • docetaxel • Perjeta (pertuzumab)
    almost3years
    Benign vs malignant pancreatic lesions: Molecular insights to an ongoing debate. (PubMed, World J Gastrointest Surg)
    Molecular markers can also provide an insight to the prognosis. For instance, the loss of SMAD4 is associated with a poor outcome whereas mutations in MLL, MLL2, MLL3, and ARID1A are associated with improved survival.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • KMT2D (Lysine Methyltransferase 2D) • MUC1 (Mucin 1) • SMAD4 (SMAD family member 4) • KMT2C (Lysine Methyltransferase 2C) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • MUC4 (Mucin 4, Cell Surface Associated) • KRT19 (Keratin 19) • MUC5AC (Mucin 5AC)
    |
    TP53 mutation • KRAS mutation • ARID1A mutation • KMT2D mutation • MLL2 mutation • MLL mutation • MUC4 expression